SRx Health director receives stock awards

Conway Simon Alexander Malcolm reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 04/03/2026 - 08:29 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Conway Simon Alexander Malcolm reported acquisition or exercise transactions in this Form 4 filing.

SRx Health Solutions, Inc. director Conway Simon Alexander Malcolm reported two compensation-related stock awards of common shares. On August 25, 2025, he received 154,128 shares at a stated value of $0.40 per share, and on December 3, 2025, he received 630,000 shares at $0.39 per share. These are classified as grants or awards, not open‑market purchases. Following the most recent award, he directly holds 834,792 common shares.

Insider Trade Summary

Grant/Award: 784,128 shares

Grant/Award 2 txns

Insider Conway Simon Alexander Malcolm

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	630,000	$0.39	$246K
Grant/Award	Common Stock	154,128	$0.40	$62K

Holdings After Transaction: Common Stock — 834,792 shares (Direct)

Holdings Before and After: Common Stock, 50,664 to 834,792 shares (Direct)

Key Figures

December 3, 2025 award: 630,000 shares at $0.39 August 25, 2025 award: 154,128 shares at $0.40 Shares held after latest award: 834,792 shares

3 metrics

December 3, 2025 award 630,000 shares at $0.39 Grant/award of SRx Health common stock to director

August 25, 2025 award 154,128 shares at $0.40 Grant/award of SRx Health common stock to director

Shares held after latest award 834,792 shares Director’s direct ownership following December 3, 2025 grant

Key Terms

Form 4, grant, award, or other acquisition, Common Stock

3 terms

Form 4 regulatory

"This SRx Health Form 4 shows director Conway Simon Alexander Malcolm received two stock awards"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

grant, award, or other acquisition financial

"Both transactions are classified as “grant, award, or other acquisition” of common stock"

Common Stock financial

"The Form 4 shows director Conway Simon Alexander Malcolm received two stock awards of SRx Health common shares"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did SRx Health (SRXH) report in this Form 4?

The Form 4 shows director Conway Simon Alexander Malcolm received two stock awards of SRx Health common shares. He was granted 154,128 shares on August 25, 2025 and 630,000 shares on December 3, 2025 as non‑market, compensation-related acquisitions.

How many SRx Health (SRXH) shares does the director own after these awards?

After the December 3, 2025 award, director Conway Simon Alexander Malcolm directly holds 834,792 shares of SRx Health common stock. This figure reflects his position immediately following the latest reported grant, according to the share balance disclosed in the Form 4.

Were the SRx Health (SRXH) insider transactions open-market buys or compensation grants?

Both transactions are classified as “grant, award, or other acquisition” of common stock, not open‑market purchases. They represent equity compensation awards to director Conway Simon Alexander Malcolm rather than discretionary buying or selling of SRx Health shares in the market.

What were the reference prices for the SRx Health (SRXH) stock awards?

The 154,128-share award dated August 25, 2025 used a stated price of $0.40 per share. The 630,000-share award dated December 3, 2025 used a stated price of $0.39 per share. These prices typically reflect grant valuation, not necessarily actual market trades.

Does this SRx Health (SRXH) Form 4 show any insider sales of stock?

No insider sales are reported. The Form 4 lists two acquisitions coded as awards (transaction code A) of SRx Health common stock. There are no open‑market sales, tax‑withholding dispositions, gifts, or derivative exercises disclosed in the transaction summary.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Conway Simon Alexander Malcolm

(Last) (First) (Middle)

10 GLOUCESTER PLACE

(Street)

LONDON W1U 8EZ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
SRx Health Solutions, Inc. [ SRXH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		A		630,000	A	$0.39	834,792	D
Common Stock	08/25/2025		A		154,128	A	$0.4	204,792	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	Carolina Martinez, Attorney-in- Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)